

Vladimir Tesar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/948529/publications.pdf>

Version: 2024-02-01

226
papers

25,928
citations

23500

58
h-index

6818

155
g-index

235
all docs

235
docs citations

235
times ranked

17272
citing authors

#	ARTICLE	IF	CITATIONS
1	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. <i>Lancet</i> , The, 2011, 377, 2181-2192.	6.3	2,087
2	Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. <i>New England Journal of Medicine</i> , 2009, 360, 1395-1407.	13.9	1,781
3	Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. <i>New England Journal of Medicine</i> , 2010, 363, 211-220.	13.9	1,471
4	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 736-745.	0.5	1,265
5	A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies. <i>New England Journal of Medicine</i> , 2003, 349, 36-44.	13.9	1,239
6	EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1583-1594.	0.5	940
7	Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 1103-1112.	3.0	923
8	Joint European League Against Rheumatism and European Renal Association "European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1771-1782.	0.5	868
9	Genetically Distinct Subsets within ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2012, 367, 214-223.	13.9	820
10	Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody "Associated Vasculitis. <i>Annals of Internal Medicine</i> , 2009, 150, 670.	2.0	790
11	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. <i>Kidney International</i> , 2021, 100, S1-S276.	2.6	782
12	Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis. <i>New England Journal of Medicine</i> , 2011, 365, 1886-1895.	13.9	544
13	Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody "Associated Vasculitis. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 2381.	3.8	524
14	Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. <i>Nature Genetics</i> , 2014, 46, 1187-1196.	9.4	505
15	Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2020, 382, 622-631.	13.9	465
16	2019 Update of the Joint European League Against Rheumatism and European Renal Association "European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 713-723.	0.5	463
17	Avacopan for the Treatment of ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2021, 384, 599-609.	13.9	461
18	Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2756-2767.	3.0	448

#	ARTICLE	IF	CITATIONS
19	Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1930-1942.	13.9	420
20	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019, 393, 1937-1947.	6.3	408
21	Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. <i>Kidney International</i> , 2014, 86, 828-836.	2.6	373
22	Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 955-960.	0.5	348
23	Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. <i>Kidney International</i> , 2021, 100, 753-779.	2.6	325
24	Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis. <i>PLoS Genetics</i> , 2012, 8, e1002765.	1.5	301
25	Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. <i>Lancet, The</i> , 2017, 389, 2117-2127.	6.3	278
26	The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2015, 3, 687-696.	5.5	221
27	Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1178-1182.	0.5	217
28	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 268-280.	2.6	198
29	The Czech registry of renal biopsies. Occurrence of renal diseases in the years 1994-2000. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 3040-3049.	0.4	187
30	Corticosteroids in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2248-2258.	3.0	187
31	Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1839-1844.	0.4	177
32	Advanced glycoxidation end products in chronic diseases—clinical chemistry and genetic background. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2005, 579, 37-46.	0.4	167
33	Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 399-405.	0.5	165
34	High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3115-3121.	0.4	164
35	Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. <i>Nature Communications</i> , 2019, 10, 5120.	5.8	160
36	Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. <i>Kidney International</i> , 2017, 92, 693-702.	2.6	154

#	ARTICLE	IF	CITATIONS
37	Soluble Receptor for Advanced Glycation End Products in Patients With Decreased Renal Function. <i>American Journal of Kidney Diseases</i> , 2006, 47, 406-411.	2.1	146
38	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1744-1750.	0.5	139
39	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 281-295.	2.6	135
40	Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey. <i>BMJ: British Medical Journal</i> , 2019, 367, I5873.	2.4	131
41	DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2745-2754.	3.0	128
42	The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. <i>Nature Communications</i> , 2020, 11, 1600.	5.8	120
43	Renal Biopsy in 2015 - From Epidemiology to Evidence-Based Indications. <i>American Journal of Nephrology</i> , 2016, 43, 1-19.	1.4	106
44	Renal biopsy in patients with diabetes: a pooled meta-analysis of 48 studies. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw070.	0.4	103
45	Lupus nephritis management guidelines compared. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 904-913.	0.4	97
46	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1243-1249.	0.5	93
47	A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. <i>Rheumatology</i> , 2011, 50, 899-905.	0.9	89
48	Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 952-963.	2.9	82
49	Matrix Metalloproteinases in Renal Diseases: A Critical Appraisal. <i>Kidney and Blood Pressure Research</i> , 2019, 44, 298-330.	0.9	80
50	Outcome and Treatment of Elderly Patients with ANCA-Associated Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1128-1135.	2.2	75
51	Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1125-1130.	0.5	72
52	Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort. <i>Pediatric Nephrology</i> , 2017, 32, 139-150.	0.9	71
53	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 393-399.	2.9	71
54	Receptor for advanced glycation end products-soluble form and gene polymorphisms in chronic haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2020-2026.	0.4	68

#	ARTICLE	IF	CITATIONS
55	Markers for the progression of IgA nephropathy. <i>Journal of Nephrology</i> , 2016, 29, 535-541.	0.9	66
56	Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1002-1009.	0.4	66
57	A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 179-186.	0.4	64
58	Peritoneal Dialysis Use and Practice Patterns: An International Survey Study. <i>American Journal of Kidney Diseases</i> , 2021, 77, 315-325.	2.1	62
59	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 400-406.	2.9	62
60	Tonsillectomy in a European Cohort of 1,147 Patients with IgA Nephropathy. <i>Nephron</i> , 2016, 132, 15-24.	0.9	60
61	Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 3404-3413.	3.0	60
62	Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2016, 68, 371-380.	2.1	57
63	Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2014, 64, 40-48.	2.1	55
64	Nationwide biopsy survey of renal diseases in the Czech Republic during the years 1994â€“2011. <i>Journal of Nephrology</i> , 2015, 28, 39-49.	0.9	55
65	Long-Term Follow-Up of Cyclophosphamide Compared with Azathioprine for Initial Maintenance Therapy in ANCA-Associated Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1571-1576.	2.2	53
66	Characteristics and Outcomes of Granulomatosis With Polyangiitis (Wegener) and Microscopic Polyangiitis Requiring Renal Replacement Therapy: Results From the European Renal Associationâ€™European Dialysis and Transplant Association Registry. <i>American Journal of Kidney Diseases</i> , 2015, 66, 613-620.	2.1	52
67	Glycooxidation and inflammation in chronic haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 2577-2581.	0.4	47
68	Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 80-85.	0.5	47
69	A European multicentre and open-label controlled randomized trial to evaluate the efficacy of sequential treatment with Tacrolimusâ€™Rituximab versus steroids plus cyclophosphamide in patients with primary Membranous Nephropathy: the STARMEN study. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 503-510.	1.4	47
70	Developments in the Histopathological Classification of ANCA-Associated Glomerulonephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1103-1111.	2.2	47
71	Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin A nephropathy. <i>Kidney International</i> , 2021, 99, 1179-1188.	2.6	47
72	Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes. <i>Arthritis and Rheumatology</i> , 2019, 71, 411-419.	2.9	45

#	ARTICLE	IF	CITATIONS
73	Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Kidney International Reports</i> , 2018, 3, 1039-1049.	0.4	41
74	Treatment of Severe Renal Disease in ANCA Positive and Negative Small Vessel Vasculitis with Rituximab. <i>American Journal of Nephrology</i> , 2015, 41, 296-301.	1.4	39
75	Tissue ischemia worsens during hemodialysis in end-stage renal disease patients. <i>Journal of Vascular Access</i> , 2017, 18, 47-51.	0.5	39
76	Rituximab in Membranous Nephropathy. <i>Kidney International Reports</i> , 2021, 6, 881-893.	0.4	39
77	Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1160-1168.	0.4	38
78	Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?. <i>Autoimmunity Reviews</i> , 2020, 19, 102671.	2.5	37
79	Why Target the Gut to Treat IgA Nephropathy?. <i>Kidney International Reports</i> , 2020, 5, 1620-1624.	0.4	37
80	Urine proteomics for prediction of disease progression in patients with IgA nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, 42-52.	0.4	36
81	Vitamin D Binding Protein Is Not Involved in Vitamin D Deficiency in Patients with Chronic Kidney Disease. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	35
82	Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 436-447.	3.0	34
83	Treatment of proliferative lupus nephritis: a slowly changing landscape. <i>Nature Reviews Nephrology</i> , 2011, 7, 96-109.	4.1	33
84	Rituximab for treatment of severe renal disease in ANCA associated vasculitis. <i>Journal of Nephrology</i> , 2016, 29, 195-201.	0.9	33
85	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. <i>Kidney International</i> , 2018, 93, 1000-1007.	2.6	32
86	Repeat protocol renal biopsy in ANCA-associated renal vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1728-1732.	0.4	31
87	The retrospective analysis of 343 Czech patients with IgA nephropathy--one centre experience. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1492-1498.	0.4	29
88	Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression. <i>PLoS ONE</i> , 2019, 14, e0212254.	1.1	29
89	Lower Retinol Levels as an Independent Predictor of Mortality in Long-term Hemodialysis Patients: A Prospective Observational Cohort Study. <i>American Journal of Kidney Diseases</i> , 2010, 56, 513-521.	2.1	28
90	Avacopan in the treatment of ANCA-associated vasculitis. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 491-496.	1.9	28

#	ARTICLE	IF	CITATIONS
91	Lupus Nephritis: A Different Disease in European Patients?. <i>Kidney Diseases (Basel, Switzerland)</i> , 2015, 1, 110-118.	1.2	27
92	Outcome of Thirty Patients with ANCA-Associated Renal Vasculitis Admitted to the Intensive Care Unit. <i>Renal Failure</i> , 2008, 30, 890-895.	0.8	25
93	Intracellular Cytokine Production in ANCA-associated Vasculitis: Low Levels of Interleukin-10 in Remission Are Associated with a Higher Relapse Rate in the Long-term Follow-up. <i>Archives of Medical Research</i> , 2009, 40, 276-284.	1.5	25
94	Current status of health systems financing and oversight for end-stage kidney disease care: a cross-sectional global survey. <i>BMJ Open</i> , 2021, 11, e047245.	0.8	25
95	Framework for establishing integrated kidney care programs in low- and middle-income countries. <i>Kidney International Supplements</i> , 2020, 10, e19-e23.	4.6	24
96	HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. <i>Kidney International</i> , 2021, 99, 671-685.	2.6	24
97	Autoantibodies in the Diagnosis, Monitoring, and Treatment of Membranous Nephropathy. <i>Frontiers in Immunology</i> , 2021, 12, 593288.	2.2	24
98	Hemodialysis Use and Practice Patterns: An International Survey Study. <i>American Journal of Kidney Diseases</i> , 2021, 77, 326-335.e1.	2.1	24
99	Endotrophin, a collagen type VI-derived matrikine, reflects the degree of renal fibrosis in patients with IgA nephropathy and in patients with ANCA-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1099-1108.	0.4	24
100	HMGB1, S100 proteins and other RAGE ligands in cancer - markers, mediators and putative therapeutic targets. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2016, 160, 1-10.	0.2	24
101	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. <i>RMD Open</i> , 2017, 3, e000449.	1.8	23
102	NETosis provides the link between activation of neutrophils on hemodialysis membrane and comorbidities in dialyzed patients. <i>Inflammation Research</i> , 2017, 66, 369-378.	1.6	23
103	Considerations on equity in management of end-stage kidney disease in low- and middle-income countries. <i>Kidney International Supplements</i> , 2020, 10, e63-e71.	4.6	23
104	Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open-Label Phase 2a Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 829-838.	3.0	23
105	Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1684-1687.e10.	1.5	22
106	Toward Noninvasive Diagnosis of IgA Nephropathy: A Pilot Urinary Metabolomic and Proteomic Study. <i>Disease Markers</i> , 2016, 2016, 1-9.	0.6	21
107	Emerging Modes of Treatment of IgA Nephropathy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9064.	1.8	21
108	Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1400-1410.	0.4	21

#	ARTICLE	IF	CITATIONS
109	Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up. <i>Arthritis Research and Therapy</i> , 2015, 17, 371.	1.6	20
110	Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 301-308.	0.4	20
111	Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. <i>Rheumatology</i> , 2021, 60, 4654-4661.	0.9	20
112	Pregnancy-Associated Plasma Protein A as an Independent Mortality Predictor in Long-Term Hemodialysis Patients. <i>Kidney and Blood Pressure Research</i> , 2012, 35, 192-201.	0.9	19
113	Placental growth factor, pregnancy-associated plasma protein-A, soluble receptor for advanced glycation end products, extracellular newly identified receptor for receptor for advanced glycation end products binding protein and high mobility group box 1 levels in patients with acute kidney injury: a cross sectional study. <i>BMC Nephrology</i> , 2013, 14, 245.	0.8	19
114	Addition of ETA receptor blockade increases renoprotection provided by renin-angiotensin system blockade in 5/6 nephrectomized Ren-2 transgenic rats. <i>Life Sciences</i> , 2014, 118, 297-305.	2.0	19
115	The Effect of Lowering LDL Cholesterol on Vascular Access Patency. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 914-919.	2.2	19
116	Limitations of Standard Immunosuppressive Treatment in ANCA-Associated Vasculitis and Lupus Nephritis. <i>Nephron Clinical Practice</i> , 2015, 128, 205-215.	2.3	19
117	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2016, 67, 576-584.	2.1	19
118	Defective gene expression of the membrane complement inhibitor CD46 in patients with progressive immunoglobulin A nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 587-596.	0.4	19
119	Recent Progress in the Pathogenesis of Nephrotic Proteinuria. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2008, 45, 139-220.	2.7	18
120	Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry. <i>American Journal of Kidney Diseases</i> , 2019, 73, 184-193.	2.1	18
121	Availability, Accessibility, and Quality of Conservative Kidney Management Worldwide. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 79-87.	2.2	18
122	Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in kidney disease. <i>Advances in Clinical Chemistry</i> , 2021, 105, 141-212.	1.8	17
123	Resting energy expenditure and thermal balance during isothermic and thermoneutral haemodialysis heat production does not explain increased body temperature during haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3553-3560.	0.4	16
124	Genetic Predisposition to Advanced Glycation End Products Toxicity Is Related to Prognosis of Chronic Hemodialysis Patients. <i>Kidney and Blood Pressure Research</i> , 2010, 33, 30-36.	0.9	16
125	Associations of Serum Levels of Advanced Glycation end Products with Nutrition Markers and Anemia in Patients with Chronic Kidney Disease. <i>Renal Failure</i> , 2011, 33, 131-137.	0.8	16
126	The effect of high-flow arteriovenous fistulas on systemic haemodynamics and brain oxygenation. <i>ESC Heart Failure</i> , 2021, 8, 2165-2171.	1.4	16

#	ARTICLE	IF	CITATIONS
127	Association of advanced vasculopathy and transforming growth factor-beta1 gene expression with immunoglobulin A nephropathy progression. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 573-579.	0.4	15
128	The coincidence of IgA nephropathy and Fabry disease. <i>BMC Nephrology</i> , 2013, 14, 6.	0.8	15
129	Nephrology in the Eastern and Central European region: challenges and opportunities. <i>Kidney International</i> , 2019, 96, 287-290.	2.6	15
130	Englishâ€“Latin nomenclature conundrum: should we use kidneylogy, kidneylogist?. <i>Kidney International</i> , 2020, 98, 1352-1353.	2.6	15
131	Autosomal Dominant Polycystic Kidney Disease: From Pathophysiology of Cystogenesis to Advances in the Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3317.	1.8	15
132	New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies. <i>Journal of Clinical Medicine</i> , 2022, 11, 2810.	1.0	15
133	Serum S100A12 (EN-RAGE) Levels in Patients with Decreased Renal Function and Subclinical Chronic Inflammatory Disease. <i>Kidney and Blood Pressure Research</i> , 2011, 34, 457-464.	0.9	14
134	Long-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study. <i>Arthritis Research and Therapy</i> , 2016, 18, 168.	1.6	14
135	Does the renal expression of Toll-like receptors play a role in patients with IgA nephropathy?. <i>Journal of Nephrology</i> , 2020, 33, 307-316.	0.9	14
136	Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 920-925.	0.4	14
137	Rokitansky and his first description of polyarteritis nodosa. <i>Journal of Nephrology</i> , 2004, 17, 172-4.	0.9	14
138	Renal transplantation in anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2014, 30 Suppl 1, i159-63.	0.4	13
139	Predictors of Renal Outcomes in Sclerotic Class Anti-Neutrophil Cytoplasmic Antibody Glomerulonephritis. <i>American Journal of Nephrology</i> , 2018, 48, 465-471.	1.4	13
140	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. <i>Kidney International</i> , 2019, 96, 170-179.	2.6	13
141	EN-RAGE (extracellular newly identified receptor for advanced glycation end-products binding) Tj ETQq1 1 0.784314 rgBT /Overlock 101 Clinical Biochemistry, 2012, 45, 556-560.	0.8	12
142	Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients. <i>Atherosclerosis</i> , 2014, 236, 263-269.	0.4	12
143	Belimumab in the management of systemic lupus erythematosus â€“ an update. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 901-908.	1.4	12
144	Lessons learned from the failure of several recent trials with biologic treatment in systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 989-996.	1.4	12

#	ARTICLE	IF	CITATIONS
145	Mass spectrometry-based proteomic exploration of the small urinary extracellular vesicles in ANCA-associated vasculitis in comparison with total urine. <i>Journal of Proteomics</i> , 2021, 233, 104067.	1.2	12
146	Reduction of arteriovenous access blood flow leads to biventricular unloading in haemodialysis patients. <i>International Journal of Cardiology</i> , 2021, 334, 148-153.	0.8	12
147	Plasma exchange in ANCA-associated vasculitis: the pro position. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 227-231.	0.4	12
148	Building a network of ADPKD reference centres across Europe: the EuroCYST initiative. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, iv26-iv32.	0.4	11
149	COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1758-1760.	0.4	11
150	Soluble cytokine receptors in renal vasculitis and lupus nephritis. <i>Medical Science Monitor</i> , 2002, 8, BR24-9.	0.5	11
151	Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2190-2200.	0.4	11
152	Complement Inhibition in ANCA-Associated Vasculitis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
153	Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease. <i>Kidney and Blood Pressure Research</i> , 2018, 43, 329-349.	0.9	10
154	Mutational screening of inverted formin 2 in adult-onset focal segmental glomerulosclerosis or minimal change patients from the Czech Republic. <i>BMC Medical Genetics</i> , 2018, 19, 147.	2.1	10
155	A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 23-35.	1.4	10
156	The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 551-561.	0.4	10
157	Effect of Hemodiafiltration on Pregnancy-Associated Plasma Protein A (PAPP-A) and Related Parameters. <i>Renal Failure</i> , 2006, 28, 715-721.	0.8	9
158	Pregnancy-associated plasma protein A: spotlight on kidney diseases. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 1183-90.	1.4	9
159	IgA Nephropathy in Czech Patients - Are We Able Reliably Predict the Outcome?. <i>Kidney and Blood Pressure Research</i> , 2014, 39, 555-562.	0.9	9
160	Renal Transplantation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Current Perspectives. <i>Kidney and Blood Pressure Research</i> , 2020, 45, 157-165.	0.9	9
161	Outcome of 313 Czech Patients With IgA Nephropathy After Renal Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 726215.	2.2	9
162	Availability, coverage, and scope of health information systems for kidney care across world countries and regions. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, 159-167.	0.4	9

#	ARTICLE	IF	CITATIONS
163	Early Identification of CKD—A Scoping Review of the Global Populations. <i>Kidney International Reports</i> , 2022, 7, 1341-1353.	0.4	9
164	Does Renal Function Influence Plasma Levels of Advanced Glycation and Oxidation Protein Products in Patients with Chronic Rheumatic Diseases Complicated by Secondary Amyloidosis?. <i>Kidney and Blood Pressure Research</i> , 2007, 30, 1-7.	0.9	8
165	Mycophenolate Mofetil in Low Doses Stabilizes and Improves Antineutrophil Cytoplasmic Antibody-associated Vasculitis and Lupus Nephritis. <i>Archives of Medical Research</i> , 2008, 39, 115-119.	1.5	8
166	ANCA Vasculitis Induction Management During the COVID-19 Pandemic. <i>Kidney International Reports</i> , 2021, 6, 2903-2907.	0.4	8
167	LONG TERM TREATMENT OF IgA NEPHROPATHY WITH CYCLOSPORINE A. <i>Renal Failure</i> , 2000, 22, 55-62.	0.8	7
168	MO041URINE PROTEOMICS FOR PREDICTION OF DISEASE PROGRESSION IN PATIENTS WITH IGA NEPHROPATHY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	7
169	Chronic kidney disease and pregnancy outcomes. <i>Scientific Reports</i> , 2021, 11, 21299.	1.6	7
170	The management of membranous nephropathy—an update. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1033-1042.	0.4	7
171	Indication for corticosteroids in IgA nephropathy: validation in the European VALIGA cohort of a treatment score based on the Oxford classification. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1195-1197.	0.4	7
172	Understanding Histopathologic Characteristics to Predict Renal Outcomes in Lupus Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 711-712.	2.2	6
173	FRIO193—2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		6
174	Tolerance and safety of rapid 2-hour infusion of rituximab in patients with kidney-affecting autoimmune diseases and glomerulonephritides: a single-centre experience. <i>European Journal of Hospital Pharmacy</i> , 2019, 26, 210-213.	0.5	6
175	Treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1519-1521.	2.2	6
176	SGLT2 inhibitors in non-diabetic kidney disease. <i>Advances in Clinical and Experimental Medicine</i> , 2022, 31, 105-107.	0.6	6
177	Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis. <i>Kidney Medicine</i> , 2022, 4, 100457.	1.0	6
178	Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis — still of value for our patients?. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1683-1702.	0.9	5
179	Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis. <i>Journal of Rheumatology</i> , 2020, 47, 580-588.	1.0	5
180	Influence of losartan and enalapril on urinary excretion of 8-isoprostane in experimental nephrotic syndrome. <i>Medical Science Monitor</i> , 2002, 8, BR69-74.	0.5	5

#	ARTICLE	IF	CITATIONS
181	Immunotactoid glomerulonephritis as a cause of acute renal failure. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1016-1017.	0.4	4
182	Secondary Membranous Nephropathy – One Center Experience. <i>Renal Failure</i> , 2005, 27, 397-402.	0.8	4
183	Rare transformation in repeat renal biopsies suggests a different pathogenesis of segmental and global lesions in proliferative lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2929-2932.	0.4	4
184	Immunosuppressive Treatment in C3 Glomerulopathy: Time to Reconsider Our Approach. <i>American Journal of Nephrology</i> , 2017, 46, 93-95.	1.4	4
185	The switch from proteasome to immunoproteasome is increased in circulating cells of patients with fast progressive immunoglobulin A nephropathy and associated with defective CD46 expression. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1389-1398.	0.4	4
186	Analysis of microRNAs in Small Urinary Extracellular Vesicles and Their Potential Roles in Pathogenesis of Renal ANCA-Associated Vasculitis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4344.	1.8	4
187	Peritoneal dialysis in the elderly – is its underutilization justified?. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3473-3476.	0.4	3
188	ANCA-Associated Renal Vasculitis - An Update. <i>Contributions To Nephrology</i> , 2013, 181, 216-228.	1.1	3
189	Cys327Cys polymorphism of the PAPP-A gene (pregnancy associated plasma protein A) is related to mortality of long term hemodialysis patients. <i>Clinical Biochemistry</i> , 2014, 47, 578-583.	0.8	3
190	Moderator's view: Should all patients with ANCA-associated vasculitis be primarily treated with rituximab?. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1088-1090.	0.4	3
191	Urine sCD163: a window onto glomerular inflammation. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1970-1972.	0.4	3
192	Pregnancy-Associated Plasma Protein A2 in Hemodialysis Patients: Significance for Prognosis. <i>Kidney and Blood Pressure Research</i> , 2017, 42, 509-518.	0.9	3
193	Addition of Endothelin A-Receptor Blockade Spoils the Beneficial Effect of Combined Renin-Angiotensin and Soluble Epoxide Hydrolase Inhibition: Studies on the Course of Chronic Kidney Disease in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats. <i>Kidney and Blood Pressure Research</i> , 2019, 44, 1493-1505.	0.9	3
194	Vancomycin pharmacokinetics in patients treated with intermittent haemodialysis based on therapeutic drug monitoring. <i>Journal of Chemotherapy</i> , 2022, 34, 149-156.	0.7	3
195	Real world analysis of high-cut-off (HCO) hemodialysis with bortezomib-based backbone therapy in patients with multiple myeloma and acute kidney injury. <i>Journal of Nephrology</i> , 2021, 34, 1263-1270.	0.9	3
196	Incidence of Kidney Replacement Therapy and Subsequent Outcomes Among Patients With Systemic Lupus Erythematosus: Findings From the ERA Registry. <i>American Journal of Kidney Diseases</i> , 2022, 79, 635-645.	2.1	3
197	Assessing the impact of screening, early identification and intervention programmes for chronic kidney disease: protocol for a scoping review. <i>BMJ Open</i> , 2021, 11, e053857.	0.8	3
198	Management of Elderly Patients with Rapidly Progressive Glomerulonephritis. <i>Blood Purification</i> , 2018, 45, 213-217.	0.9	2

#	ARTICLE	IF	CITATIONS
199	Assessment of renal function before contrast media injection: right decisions based on inaccurate estimates. <i>European Radiology</i> , 2019, 29, 3192-3199.	2.3	2
200	Dosing of Aminoglycosides in Chronic Kidney Disease and End-Stage Renal Disease Patients Treated with Intermittent Hemodialysis. <i>Kidney and Blood Pressure Research</i> , 2022, 47, 448-458.	0.9	2
201	The Influence of Pefloxacin on Experimental Adriamycin-Induced Nephrotic Syndrome in Rats. <i>Renal Failure</i> , 1996, 18, 195-199.	0.8	1
202	Unusual manifestation of AL amyloidosis – stenosis of inferior vena cava. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1430-1433.	0.4	1
203	Biosimilars and Renal Health Care in the Countries of Central and Eastern Europe. <i>Kidney and Blood Pressure Research</i> , 2007, 30, 2-5.	0.9	1
204	Pregnancy-associated plasma protein A (PAPP-A) and soluble receptor for advanced glycation end products (sRAGE) – intra- and inter-individual variability in chronic hemodialysis patients. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2012, 72, 296-303.	0.6	1
205	Moderator's view: Cyclophosphamide in lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1058-1061.	0.4	1
206	Cardiorenal interactions. <i>Cor Et Vasa</i> , 2018, 60, e144-e147.	0.1	1
207	FP275A BIOMARKER OF COLLAGEN TYPE III DEGRADATION DECREASES WITH INCREASING FIBROSIS IN THE KIDNEY OF PATIENTS WITH IgA NEPHROPATHY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i124-i124.	0.4	1
208	Lupus nephritis and ANCA-associated vasculitis: towards precision medicine?. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 37-43.	0.4	1
209	Extrarenal complications of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) and their impact on the outcome of the patients. <i>Journal of Nephrology</i> , 2022, 35, 1065-1068.	0.9	1
210	Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis as a Complication of Home Parenteral Nutrition. <i>Case Reports in Nephrology and Dialysis</i> , 2022, 12, 22-30.	0.3	1
211	Checking heart failure in patients with advanced chronic kidney disease (Czech HF-CKD): Study protocol. <i>Journal of Vascular Access</i> , 2024, 25, 294-302.	0.5	1
212	Laudatio to Professor Otto Schöck on the Occasion of His 80th Birthday. <i>Kidney and Blood Pressure Research</i> , 2006, 29, 327-328.	0.9	0
213	FP124MATRIX METALLOPROTEINASES (MMP-2, 3, 7, 9) AND THEIR TISSUE INHIBITORS (TIMP-1, 2) IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii108-iii108.	0.4	0
214	MO040ASSOCIATION OF A TNFSF13B (BAFF) REGULATORY REGION SINGLE NUCLEOTIDE POLYMORPHISMS WITH RESPONSE TO RITUXIMAB IN ANCA-ASSOCIATED VASCULITIS. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i45-i46.	0.4	0
215	MP170CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH ANCA-ASSOCIATED VASCULITIS TREATED WITH PLASMA EXCHANGE IN A SINGLE CENTRE. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i397-i397.	0.4	0
216	MP207SERUM MATRIX METALLOPROTEINASES MMP-2 AND MMP-9 AND METALLOPROTEINASE TISSUE INHIBITORS TIMP-1 AND TIMP-2 IN PATIENTS WITH ACUTE KIDNEY INJURY. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i409-i409.	0.4	0

#	ARTICLE	IF	CITATIONS
217	SP035THE ROLE OF S100 PROTEINS AND MATRIX METALLOPROTEINASE AND THEIR INHIBITORSIN THE PATHOGENESIS OF LUPUS NEPHRITIS. Nephrology Dialysis Transplantation, 2018, 33, i357-i358.	0.4	0
218	SP174DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE OF A PANEL OF SERUM AND URINARY BIOMARKERS IN ANCA-ASSOCIATED VASCULITIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
219	185.â€fGENETIC EVIDENCE OF EOSINOPHIL NUMBER UNDERPINNING PR3-AAV AND PLAUSIBLE HOST GENETIC PREDISPOSITION TO MICROBIAL DRIVERS OF DISEASE. Rheumatology, 2019, 58, .	0.9	0
220	118.â€fVALIDATION OF THE RENAL RISK SCORE FOR ANCA-ASSOCIATED GLOMERULONEPHRITIS. Rheumatology, 2019, 58, .	0.9	0
221	FRIO192â€f...A SYSTEMATIC LITERATURE REVIEW TO INFORM THE 2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
222	Nephrology in the Czech Republic. , 2021, , 499-509.		0
223	Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy. European Journal of Clinical Pharmacology, 2022, 78, 89-98.	0.8	0
224	Granulomatosis with polyangiitis mimicking cancer: a diagnostic dilemma. Journal of Nephrology, 2022, 35, 675-678.	0.9	0
225	Gliflozins slow down the progression of diabetic kidney disease. Vnitřni Lekarstvi, 2017, 63, 723-727.	0.1	0
226	Pulmonaryâ€renal syndrome. Vnitřni Lekarstvi, 2020, 66, e20-e25.	0.1	0